Compare · ABT vs JUNS
ABT vs JUNS
Side-by-side comparison of Abbott Laboratories (ABT) and Jupiter Neurosciences Inc. (JUNS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and JUNS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $154.95B, about 18051.4x JUNS ($8.6M).
- Over the past year, ABT is down 32.3% and JUNS is down 94.0% - ABT leads by 61.7 points.
- JUNS has been more active in the news (15 items in the past 4 weeks vs 10 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 0 for JUNS).
- Company
- Abbott Laboratories
- Jupiter Neurosciences Inc.
- Price
- $88.95-3.44%
- $0.18-2.84%
- Market cap
- $154.95B
- $8.6M
- 1M return
- -0.77%
- -20.35%
- 1Y return
- -32.34%
- -94.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 10
- 15
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
- Abbott hosts conference call for second-quarter earnings
- ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing
Latest JUNS
- Chief Administrative Officer Rosen Alexander Gustaf Erik converted options into 261,161 shares, increasing direct ownership by 73% to 617,411 units (SEC Form 4)
- Director Kampf Julie B. converted options into 82,875 shares (SEC Form 4)
- Director Weis Holger converted options into 85,800 shares, increasing direct ownership by 796% to 96,581 units (SEC Form 4)
- Director Hemmerly Nicholas H. converted options into 95,550 shares (SEC Form 4)
- Chief Scientific Officer Hayward Marshall A. converted options into 1,014,195 shares, increasing direct ownership by 51% to 2,995,077 units (SEC Form 4)
- SEC Form EFFECT filed by Jupiter Neurosciences Inc.
- Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
- SEC Form 4 filed by Director Philipson Tomas Jan
- SEC Form 3 filed by new insider Philipson Tomas Jan
- SEC Form 424B3 filed by Jupiter Neurosciences Inc.